The impact of the molecular profile and treatment of older and fragile patients with relapsed/refractory FLT3-mutated AML
In this MEDtalk, Marina Konopleva, Professor at Montefiore Einstein Cancer Center in New York, gives her perspective on the impact of the molecular profile for patients with relapsed/refractory AML. You can also hear her treatment recommendation for older and fragile patients with relapsed/refractory FLT3-mutated AML and what we can expect during the next one to three years.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
